Harnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphoma

Bortezomib (BZM) is the first proteasome inhibitor approved for relapsed Mantle Cell Lymphoma (MCL) with durable responses seen in 30%–50% of patients. Given that a large proportion of patients will not respond, BZM resistance is a significant barrier to use this agent in MCL. We hypothesized that a...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Leshchenko, Violetta V., Kuo, Pei-Yu, Jiang, Zewei, Weniger, Marc A., Overbey, Jessica, Dunleavy, Kieron, Wilson, Wyndham H., Wiestner, Adrian, Parekh, Samir
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2015
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4694993/
https://ncbi.nlm.nih.gov/pubmed/25714012
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars